J. Med. Chem. 48: 2336–2345.39 39 Wani, M.C., Taylor, H.L., Wall, M.E. et al. (1971). Plant antitumor agents. 6. Isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus‐Brevifolia. J. Am. Chem. Soc. 93: 2325.
40 40 Wilson, C.R., Sauer, J.‐M., and Hooser, S.B. (2001). Taxines: a review of the mechanism and toxicity of yew (Taxus spp.) alkaloids. Toxicon 39: 175–185.
41 41 Horwitz, S.B. (2019). Reflections on my life with taxol. Cell 177: 502–505.
42 42 (a) Schiff, P.B., Fant, J., and Horwitz, S.B. (1979). Promotion of microtubule assembly invitro by taxol. Nature 277: 665–667.(b) Schiff, P.B. and Horwitz, S.B. (1980). Taxol stabilizes microtubules in mouse fibroblast cells. Proc. Natl. Acad. Sci. U. S. A. 77: 1561–1565.
43 43 (a) Holton, R.A., Somoza, C., Kim, H.B. et al. (1994). First total synthesis of taxol. 1. Functionalization of the B‐ring. J. Am. Chem. Soc. 116: 1597–1598.(b) Holton, R.A., Kim, H.B., Somoza, C. et al. (1994). First total synthesis of taxol. 2. Completion of the C‐ring and D‐ring. J. Am. Chem. Soc. 116: 1599–1600.
44 44 Nicolaou, K.C., Yang, Z., Liu, J.J. et al. (1994). Total synthesis of taxol. Nature 367: 630–634.
45 45 Masters, J.J., Link, J.T., Snyder, L.B. et al. (1995). A total synthesis of taxol. Angew. Chem. Int. Ed. 34: 1723–1726.
46 46 Wender, P.A. and Mucciaro, T.P. (1992). A new and practical approach to the synthesis of taxol and taxol analogs – the pinene path. J. Am. Chem. Soc. 114: 5878–5879.
47 47 (a) Morihira, K., Hara, R., Kawahara, S. et al. (1998). Enantioselective total synthesis of taxol. J. Am. Chem. Soc. 120: 12980–12981.(b) Kusama, H., Hara, R., Kawahara, S. et al. (2000). Enantioselective total synthesis of (‐)‐taxol. J. Am. Chem. Soc. 122: 3811–3820.
48 48 Mukaiyama, T., Shiina, I., Iwadare, H. et al. (1999). Asymmetric total synthesis of Taxol (R). Chem‐Eur. J. 5: 121–161.
49 49 Takahashi, T., Okabe, T., Iwamoto, H. et al. (1997). A biomimetic approach to taxol: stereoselective synthesis of a 12‐membered ring ene‐epoxide. Isr. J. Chem. 37: 31–37.
50 50 McGuire, W.P., Rowinsky, E.K., Rosenshein, N.B. et al. (1989). Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann. Intern. Med. 111: 273–279.
51 51 Gore, A. (2006). An Inconvenient Truth: the Planetary Emergency of Global Warming and What We Can Do About It. London: Bloomsbury.
52 52 Walsh, V. and Goodman, J. (1999). Cancer chemotherapy, biodiversity, public and private property: the case of the anti‐cancer drug Taxol. Soc. Sci. Med. 49: 1215–1225.
53 53 Denis, J.N., Greene, A.E., Guenard, D. et al. (1988). A highly efficient, practical approach to natural taxol. J. Am. Chem. Soc. 110: 5917–5919.
54 54 Singla, A.K., Garg, A., and Aggarwal, D. (2002). Paclitaxel and its formulations. Int. J. Pharm. 235: 179–192.
55 55 Hirsh, V. (2014). nab‐paclitaxel for the management of patients with advanced non‐small‐cell lung cancer. Expert Rev. Anticancer Ther. 14: 129–141.
56 56 Hofle, G.H., Bedorf, N., Steinmetz, H. et al. (1996). Epothilone A and B – novel 16‐membered macrolides with cytotoxic activity: isolation, crystal structure, and conformation in solution. Angew. Chem. Int. Ed. 35: 1567–1569.
57 57 (a) Su, D.‐S., Meng, D., Bertinato, P. et al. (1997). Total synthesis of(–)‐epothilone B: an extension of the Suzuki coupling method and insights into structure–activity relationships of the epothilones. Angew. Chem. Int. Ed. 36: 757–759.(b) Balog, A., Meng, D.F., Kamenecka, T. et al. (1996). Total synthesis of (−)‐epothilone A. Angew. Chem. Int. Ed. 35: 2801–2803.
58 58 (a) Yang, Z., He, Y., Vourloumis, D. et al. (1997). Total synthesis of epothilone A: the olefin metathesis approach. Angew. Chem. Int. Ed. 36: 166–168.(b) Nicolaou, K.C., Ninkovic, S., Sarabia, F. et al. (1997). Total syntheses of epothilones A and B via a macrolactonization‐based strategy. J. Am. Chem. Soc. 119: 7974–7991.
59 59 (a) Furstner, A., Mathes, C., and Grela, K. (2001). Concise total syntheses of epothilone A and C based on alkyne metathesis. Chem. Commun.: 1057–1059.(b) Furstner, A., Mathes, C., and Lehmann, C.W. (2001). Alkyne metathesis: development of a novel molybdenum‐based catalyst system and its application to the total synthesis of epothilone A and C. Chem‐Eur. J. 7: 5299–5317.
60 60 Schinzer, D., Limberg, A., Bauer, A. et al. (1997). Total synthesis of (−)‐epothilone A. Angew. Chem. Int. Ed. 36: 523–524.
61 61 Bode, J.W. and Carreira, E.M. (2001). Stereoselective syntheses of epothilones A and B via directed nitrile oxide cycloaddition1. J. Am. Chem. Soc. 123: 3611–3612.
62 62 Mulzer, J., Mantoulidis, A., and Öhler, E. (2000). Total syntheses of epothilones B and D. J. Org. Chem. 65: 7456–7467.
63 63 Lee, F.Y.F., Borzilleri, R., Fairchild, C.R. et al. (2008). Preclinical discovery of ixabepilone, a highly active antineoplastic agent. Cancer Chemother. Pharmacol. 63: 157–166.
64 64 (a) Hirata, Y. and Uemura, D. (1986). Halichondrins – antitumor polyether macrolides from a marine sponge. Pure Appl. Chem. 58: 701–710.(b) Uemura, D., Takahashi, K., Yamamoto, T. et al. (1985). Norhalichondrin‐A – an antitumor polyether macrolide from a marine sponge. J. Am. Chem. Soc. 107: 4796–4798.
65 65 Hart, J.B., Lill, R.E., Hickford, S.J.H. et al. (2000). The halichondrins: chemistry, biology, supply and delivery. In: Drugs from the Sea (ed. N. Fusetani), 134–153. Basel: Karger.
66 66 Aicher, T.D., Buszek, K.R., Fang, F.G. et al. (1992). Total synthesis of halichondrin‐B and norhalichondrin‐B. J. Am. Chem. Soc. 114: 3162–3164.
67 67 (a) Bauer, A. (2016). Synthesis of Heterocycles in Contemporary Medicinal Chemistry (ed. Z. Časar), 209–270. Cham: Springer International Publishing.(b) Jackson, K.L., Henderson, J.A., and Phillips, A.J. (2009). The halichondrins and E7389. Chem. Rev. 109: 3044–3079.
68 68 (a) Cortes, J., O'Shaughnessy, J., Loesch, D. et al. (2011). Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open‐label randomised study. Lancet 377: 914–923.(b) Cortes, J., Twelves, C., Wanders, J. et al. (2011). Clinical response to eribulin in patients with metastatic breast cancer is independent of time to first metastatic event. EMBRACE study group. Breast 20: S48–S49.
69 69 (a) Kim, D.S., Dong, C.G., Kim, J.T. et al. (2009). New syntheses of E7389 C14‐C35 and halichondrin C14‐C38 building blocks: double‐inversion approach. J. Am. Chem. Soc. 131: 15636–15641.(b) Dong, C.G., Henderson, J.A., Kaburagi, Y. et al. (2009). New syntheses of E7389 C14‐C35 and halichondrin C14‐C38 building blocks: reductive cyclization and oxy‐Michael cyclization approaches. J. Am. Chem. Soc. 131: 15642–15646.(c) Yang, Y.R., Kim, D.S., and Kishi, Y. (2009). Second generation synthesis of C27‐C35 building block of E7389, a synthetic halichondrin analogue. Org. Lett. 11: 4516–4519.
70 70 (a) Yu, M.J., Zheng, W.J., and Seletsky, B.M. (2013). From micrograms to grams: scale‐up synthesis of eribulin mesylate. Nat. Prod. Rep. 30: 1158–1164.(b) Austad, B.C., Calkins, T.L., Chase, C.E. et al. (2013). Commercial manufacture of Halaven (R): chemoselective transformations en route to structurally complex macrocyclic ketones (vol 24, pg 333, 2013). Synlett 24, E3‐E3.(c) Fukuyama, T., Chiba, H., Kuroda, H. et al. (2016). Application of continuous flow for DIBAL‐H reduction and n‐BuLi mediated coupling reaction in the synthesis of eribulin
